Drug Trial Radar · NCT06920069
Study of Concomitant Administration of the sIPV and DTaP or MMR
Last checked: Nov 20, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2,640
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Jul 15, 2030
Study completion Jun 15, 2031
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 2 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months. Primary immunogenicity endpoints in all groups include the seroconversion rate of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies 30 days after basic immunization. Secondary immunogenicity endpoints include the seropositive rates, seroconversion rates, geometric mean titer/concentration (GMT/GMC), geometric mean fold increase (GMFI) of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies 30 days after full immunization. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.
Conditions
- Polio
- Diphteria, Tetanus and Pertussis
- MMR Vaccine
Interventions
sIPVBiological
Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose
DTaPBiological
Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose
bOPV 1,3Biological
Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose
MMR VaccineBiological
Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity index-seroconversion rate of type I anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of type II anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of type III anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of anti-DT antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of anti-TT antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of anti-PT antibodyTime frame: Between baseline and day 30 after basic vaccination
- Immunogenicity index-seroconversion rate of anti-FHA antibodyTime frame: Between baseline and day 30 after basic vaccination
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Lufeng Center for Disease Control and Prevenion
Chuxiong, Yunnan, China
Yuanmou Center for Disease Control and Prevention
Chuxiong, Yunnan, China
Wuding Center for Disease Control and Prevention
Chuxiong, Yunnan, China
Yaoan Center for Disease Control and Prevention
Chuxiong, Yunnan, China
Lancang Center for Disease Control and Prevention
Puer, Yunnan, China
Yanshan Center for Disease Control and Prevention
Wenshan, Yunnan, China
Qiubei Center for Disease Control and Prevention
Wenshan, Yunnan, China
Guangnan Center for Disease Control and Prevention
Wenshan, Yunnan, China
Mile Center for Disease Control and Prevention
Yisa, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.